Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,768.00
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.63
(
6.93%
)
Bitcoin
70,807.26
(
-4.24%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: None

Thursday, 10/21/2010 6:03:15 PM

Thursday, October 21, 2010 6:03:15 PM

Post# of 257253
MNTA: I'll say it for the umpteenth time: NVS has every reason to buy MNTA rather than splitting revenues on Lovenox and, possibly, Copaxone. MNTA's market cap represents but an asterisk on the NVS balance sheet. (After consuming Alcon)

"If we don't succeed, we run the risk of failure."
-Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now